• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

转移性去势抵抗性前列腺癌的基因组图谱的临床可操作性。

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer.

机构信息

Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium.

Laboratory of Molecular Endocrinology, KU Leuven, 3000 Leuven, Belgium.

出版信息

Cells. 2020 Nov 17;9(11):2494. doi: 10.3390/cells9112494.

DOI:10.3390/cells9112494
PMID:33212909
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7698403/
Abstract

The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.

摘要

靶向治疗的发展增加了转移性去势抵抗性前列腺癌（mCRPC）患者的治疗选择。需要有强大的预测和预后标志物来指导医生治疗 mCRPC 患者。在这篇综述中，我们揭示了 AR 通路、PI3K AKT 信号通路和 DNA 修复通路中可能的作用机制。此外，我们还就生物标志物试验设计和这类新型数据的临床应用提出了建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071f/7698403/c78c2fb74418/cells-09-02494-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071f/7698403/60372f772a36/cells-09-02494-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071f/7698403/b5ad2b82c501/cells-09-02494-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071f/7698403/c78c2fb74418/cells-09-02494-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071f/7698403/60372f772a36/cells-09-02494-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071f/7698403/b5ad2b82c501/cells-09-02494-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071f/7698403/c78c2fb74418/cells-09-02494-g003.jpg

相似文献

1
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer.转移性去势抵抗性前列腺癌的基因组图谱的临床可操作性。
Cells. 2020 Nov 17;9(11):2494. doi: 10.3390/cells9112494.
2
Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform.通过新型机器学习平台鉴定循环游离DNA中与转移性前列腺癌疾病进展相关的体细胞基因特征
Oncologist. 2021 Sep;26(9):751-760. doi: 10.1002/onco.13869. Epub 2021 Jul 7.
3
Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.循环肿瘤细胞中 AR-V7 状态、循环肿瘤细胞计数与转移性去势抵抗性前列腺癌男性患者生存的相关性。
Eur J Cancer. 2019 Nov;121:48-54. doi: 10.1016/j.ejca.2019.08.005. Epub 2019 Sep 19.
4
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer.基于全血雄激素受体的基因特征对转移性去势抵抗性前列腺癌的预后价值。
Eur Urol Focus. 2021 Jan;7(1):63-70. doi: 10.1016/j.euf.2019.04.020. Epub 2019 May 15.
5
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.脂质组学和遗传异常对转移性去势抵抗性前列腺癌临床结局的综合影响。
BMC Med. 2022 Mar 25;20(1):112. doi: 10.1186/s12916-022-02298-0.
6
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.基于正电子发射断层扫描/计算机断层扫描的雄激素受体表达和糖酵解活性评估作为转移性去势抵抗性前列腺癌的预后生物标志物。
JAMA Oncol. 2018 Feb 1;4(2):217-224. doi: 10.1001/jamaoncol.2017.3588.
7
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving Lu-PSMA-617 Radioligand Therapy.转移性去势抵抗性前列腺癌患者接受 Lu-PSMA-617 放射性配体治疗时循环肿瘤细胞的分子分析。
Theranostics. 2020 Jun 18;10(17):7645-7655. doi: 10.7150/thno.44556. eCollection 2020.
8
AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.转移性去势抵抗性前列腺癌患者全血 RNA 中的 AR-V7 转录本与醋酸阿比特龙的反应相关。
J Urol. 2017 Jan;197(1):135-142. doi: 10.1016/j.juro.2016.06.094. Epub 2016 Jul 17.
9
Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.当代用于预测和治疗指导去势抵抗性前列腺癌的分子检测。
Expert Rev Mol Diagn. 2016 Oct;16(10):1113-1120. doi: 10.1080/14737159.2016.1240031. Epub 2016 Sep 28.
10
Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.雄激素受体剪接变体 AR-V7 作为晚期前列腺癌对雄激素轴靶向治疗耐药的生物标志物。
Clin Genitourin Cancer. 2020 Feb;18(1):1-10. doi: 10.1016/j.clgc.2019.09.015. Epub 2019 Sep 26.

引用本文的文献

1
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management.转移性去势抵抗性前列腺癌：治疗和症状管理的进展。
Curr Treat Options Oncol. 2024 Jul;25(7):914-931. doi: 10.1007/s11864-024-01215-2. Epub 2024 Jun 24.
2
Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review.非转移性晚期前列腺癌根治性前列腺切除术前新辅助雄激素受体信号抑制剂：一项系统评价
J Pers Med. 2023 Apr 7;13(4):641. doi: 10.3390/jpm13040641.
3
Development and validation of a tumor immune cell infiltration-related gene signature for recurrence prediction by weighted gene co-expression network analysis in prostate cancer.

本文引用的文献

1
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.初发性高容量和低容量转移性前列腺癌的基因组图谱：STAMPEDE试验中一项两阶段可行性和患病率研究的结果
JCO Precis Oncol. 2020 Nov;4:882-897. doi: 10.1200/PO.19.00388.
2
Antibody selection influences the detection of AR-V7 in primary prostate cancer.抗体选择会影响原发性前列腺癌中 AR-V7 的检测。
Cancer Treat Res Commun. 2020;24:100186. doi: 10.1016/j.ctarc.2020.100186. Epub 2020 Jun 23.
3
Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development.
通过加权基因共表达网络分析开发和验证用于前列腺癌复发预测的肿瘤免疫细胞浸润相关基因特征
Front Genet. 2023 Mar 16;14:1067172. doi: 10.3389/fgene.2023.1067172. eCollection 2023.
4
Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance.雄激素代谢与前列腺癌抗雄激素治疗耐药中的反应。
Int J Mol Sci. 2022 Nov 4;23(21):13521. doi: 10.3390/ijms232113521.
5
The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.组织学不可知药物在转移性去势抵抗性前列腺癌治疗中的作用。
Int J Mol Sci. 2022 Aug 1;23(15):8535. doi: 10.3390/ijms23158535.
6
Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients.超越 BRCA：DNA 损伤反应与个体化治疗在胰腺癌和前列腺癌患者中的新兴意义。
Int J Mol Sci. 2022 Apr 24;23(9):4709. doi: 10.3390/ijms23094709.
7
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse.单细胞 ATAC 和 RNA 测序揭示与前列腺癌复发相关的预先存在和持续存在的细胞。
Nat Commun. 2021 Sep 6;12(1):5307. doi: 10.1038/s41467-021-25624-1.
8
Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer.前列腺癌的临床前模型：前列腺癌对雄激素受体靶向治疗的耐药性
Cancers (Basel). 2021 Feb 22;13(4):915. doi: 10.3390/cancers13040915.
9
Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy.前列腺癌诊断、预后和预测对治疗反应的最新进展。
Cells. 2020 Dec 24;10(1):20. doi: 10.3390/cells10010020.
患者来源异种移植模型中条件重编程细胞模拟神经内分泌前列腺癌的发生发展。
Cells. 2020 Jun 4;9(6):1398. doi: 10.3390/cells9061398.
4
-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.- 前列腺癌改变：标准全身疗法、聚（ADP - 核糖）聚合酶抑制剂和PD - 1抑制剂的临床特征及治疗结果
JCO Precis Oncol. 2020;4:370-381. doi: 10.1200/po.19.00399. Epub 2020 Apr 21.
5
Olaparib for Metastatic Castration-Resistant Prostate Cancer.奥拉帕利治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.
6
Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model.一种独特的神经内分泌转化前列腺循环肿瘤细胞衍生外植体模型的遗传特征。
Nat Commun. 2020 Apr 20;11(1):1884. doi: 10.1038/s41467-020-15426-2.
7
An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.原发性和转移性前列腺癌中经典和可操作的分子改变的新兴领域。
Mol Cancer Ther. 2020 Jun;19(6):1373-1382. doi: 10.1158/1535-7163.MCT-19-0531. Epub 2020 Mar 27.
8
Cellular rewiring in lethal prostate cancer: the architect of drug resistance.致命性前列腺癌中的细胞重排：耐药性的建筑师。
Nat Rev Urol. 2020 May;17(5):292-307. doi: 10.1038/s41585-020-0298-8. Epub 2020 Mar 16.
9
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.非 BRCA 种系 DNA 损伤修复基因改变与 PARP 抑制剂芦卡帕利在转移性去势抵抗性前列腺癌中的反应：来自 II 期 TRITON2 研究的分析。
Clin Cancer Res. 2020 Jun 1;26(11):2487-2496. doi: 10.1158/1078-0432.CCR-20-0394. Epub 2020 Feb 21.
10
Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure.前列腺癌中雄激素受体的深度抑制利用了性别二态性的肾脏表达来实现全身糖皮质激素暴露。
Ann Oncol. 2020 Mar;31(3):369-376. doi: 10.1016/j.annonc.2019.12.002. Epub 2020 Feb 11.